GENOMADIX ANNOUNCES FDA CLEARANCE TO MARKET THE GENOMADIX CUBE CYP2C19 SYSTEM

OTTAWA, ON, March 22, 2023 /PRNewswire/ – Genomadix, based in Ottawa, Canada, announced today the US Food and Drug Administration (FDA) granted 510(k) clearance permitting marketing of its “Genomadix CubeTM CYP2C19 System” (Cube CYP2C19 test), an automated sample-to-result PCR test. The…